| Characteristic | Number of trials |
|---|---|
| Treatment | 2,704 |
| COVID-19 vaccines | 1,752 |
| Moderate COVID-19 | 1,345 |
| COVID-19 complication support | 1,287 |
| Severe COVID-19 | 1,256 |
| COVID-19 pneumonia | 1,197 |
| Mild COVID-19 | 1,152 |
| Healthy subjects | 1,149 |
| Critical COVID-19 | 461 |
| Exposure prophylaxis (PEP/PrEP) | 418 |
| Asymptomatic COVID-19 | 254 |
| Post-COVID syndrome | 115 |
| Unspecified | 186 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
June 2022
Worldwide
as of June 3, 2022
* Definition of listed types:
Treatment: Trials intending to treat (rather than prevent) novel coronavirus (2019-nCoV, COVID-19).
COVID-19 Complication Support: Trials aiming to prevent or treat complications of COVID-19 infection, such as ARDS, Cytokine storm, AKI, Sepsis, etc.
Novel coronavirus (2019-nCoV, COVID-19) pneumonia: Trials that aim to treat or prevent pneumonia due specifically to novel coronavirus (2019-nCoV).
Severe COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms (requiring supplemental oxygen) at screening.
Moderate COVID-19: Trials enrolling subjects with confirmed COVID-19 that have moderate symptoms (respiratory symptoms but supplemental oxygen not needed) at screening.
Mild COVID-19: Trials enrolling subjects with confirmed COVID-19 that have mild upper respiratory symptoms at trial screening.
Novel coronavirus (2019-nCoV, COVID-19) vaccines: Trials with vaccines intended to prevent/treat novel coronavirus (2019-nCoV, COVID-19).
Critical COVID-19: Trials enrolling subjects with confirmed COVID-19 that have severe symptoms at screening and are in the ICU for critical support. These subjects are likely already on ventilatory support.
Exposure prophylaxis (PEP/PrEP): Trials aiming to prevent COVID-19 infection in subjects at high risk of exposure (ex. Healthcare workers). Includes trials where confirmed exposure has taken place (post-exposure prophylaxis: PEP) as well as trials treating subjects prior to first exposure (pre-exposure prophylaxis: PrEP).
Healthy subjects: Trials enrolling only healthy subjects.
Asymptomatic COVID-19: Trials enrolling subjects with confirmed COVID-19 that are asymptomatic at screening.
Post-COVID Syndrome: Trials aiming to treat Post-COVID Syndrome, including treatment of persistent lung, cardiac or kidney injury after COVID-19 infection.
Unspecified: Trials enrolling patients (not healthy volunteers) but not otherwise specified.
